GLP Watchdog

Does Aetna Pay for GLP-1 Medications? (2026)

Whether Aetna covers a GLP-1 depends on your specific plan; prior authorization is required, and members who are approved typically pay $25-$80 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Where Aetna stands[1]
Depends on the Plan
39,000,000 members · Prior authorization needed[1]
Depends on the Plan

Where Each Medication Stands[5]

MedicationWhat Aetna does
Wegovy (semaglutide)Start with the PBM, because it decides more here than the medical policy does. CVS Caremark - Aetna's PBM, both CVS Health subsidiaries - named Wegovy the PREFERRED commercial GLP-1 in July 2025, so most Aetna commercial books now step members toward it rather than away from it. The policy itself is bulletin 4774-C UDR 08-2023 v2, in force since 05/01/2024 across Non-Medicare commercial plans. An adult has to be >=18 with BMI >=30, or BMI >=27 carrying one weight-related comorbidity, and must already have completed at least 6 months in a comprehensive weight-management program before drug therapy starts. Approval lands at 7 months. Reauthorization then runs 12 months at a time and will not issue unless the chart shows baseline body weight down by 5% or more, or a 5% loss held steady. Ages 12-17 enter at BMI in the 95th percentile or greater, on the same 6-month program requirement. 4774-C carries a second, distinct cardiovascular risk-reduction pathway for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days.
Ozempic (semaglutide)Bulletin 2439-C UDR 05-2024 is the governing document, last reviewed by Aetna on 10/27/2024, and it is a type 2 diabetes policy throughout - Aetna Medicare Part D covers Ozempic on that diagnosis and NOT for off-label weight loss. The initial gate has two halves. The patient must NOT already be on stable GLP-1 maintenance of >=3 months, and must clear at least one of four entry routes: (1) metformin has failed, been contraindicated, or not been tolerated; (2) a need for combination therapy together with A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. That fourth route tracks the label's cardiovascular claim, which the bulletin frames as reducing the risk of 'major adverse cardiovascular events' in adults carrying both type 2 diabetes mellitus and established cardiovascular disease. Continuation inverts the first half: stable maintenance of >=3 months is now required, together with a demonstrated A1C reduction since GLP-1 therapy began. Quantity limits read differently by strength but land in the same place. Per 21 days: 1 pen at 2 mg/1.5 mL, 1 pen at 4 mg/3 mL, 1 pen at 8 mg/3 mL.
Zepbound (tirzepatide)Two things decide a Zepbound claim at Aetna, and the bulletin is only one of them. The bulletin is 6947-C P04-2025, effective 07/01/2025 on Non-Medicare commercial plans, superseding the older 6192-C. Adults qualify at BMI >=30, or BMI >=27 alongside a weight-related comorbid condition - hypertension, type 2 diabetes mellitus and dyslipidemia are the examples given - and must have spent at least 6 months in a comprehensive weight-management program before drug therapy. Renewal turns on documented >=5% loss from baseline body weight. A separate route covers moderate-to-severe OSA in adults with obesity at AHI >=15 events/hour. The other thing is the formulary, and it is where members actually get caught. Exception bulletin 6981-A P04-2025 takes over on eight plan-formulary codes - SF, SFC, VF, VFC, ACF, ACFC, ACCF and SCCF - where Wegovy is the preferred step instead. Behind that sits the July 2025 CVS Caremark decision that stripped Zepbound out of MOST commercial formularies, leaving one preferred GLP-1 in its place - which is why a member approved in 2024 can be denied now with nothing in their own file having changed. On the Medicare side, Part D does NOT cover Zepbound for weight loss under the statutory exclusion, though the OSA indication may be payable. From 07/01/2026 the only formulation reaching MA-PD members through the CMS Medicare GLP-1 Bridge is the KwikPen - not vials, not single-dose pens. Quantity limits hold across every strength: 1 package of 4 pens (2 mL) per 21 days, or 3 packages (6 mL) per 63 days.
Mounjaro (tirzepatide)Bulletin 5468-C UDR 05-2024, which Aetna last reviewed on 10/27/2024. As with Ozempic this is a diabetes policy: Aetna Medicare Part D pays on type 2 diabetes and NOT for off-label weight loss. Aetna writes the initial test as a negative - the patient must NOT already have held 'a stable maintenance dose' for 3 months or more - and then requires one of two routes: metformin inadequacy, intolerance or contraindication, or a need for combination therapy together with A1C >=7.5%. Continuation flips it. Stable maintenance of >=3 months becomes the requirement, paired with a demonstrated A1C reduction, and the approval period is a long one at 36 months. Quantity limits come as two windows, single-dose pens or vials either way: 4 of them (2 mL) across 21 days, or 12 (6 mL) across 63 days.
Foundayo (orforglipron)Foundayo (orforglipron) is the gap in Aetna's published record. We checked aetna.com on 2026-05-09 and found no primary-source PA bulletin for it; FDA approval came 04/01/2026 and the bulletins had not caught up. Until one appears the decision sits with the individual plan or employer, which is a different answer from a denial. Where a plan does pay, the reasonable expectation is that 4774-C, the Wegovy framework, is what gets applied: BMI >=30 on its own or >=27 with a comorbidity, 6 months of comprehensive weight-management program behind the patient, and a 5% continuation test. Medicare is the clearer half. Every Foundayo formulation sits inside the CMS Medicare GLP-1 Bridge from 07/01/2026 through 12/31/2027, at a flat $50/month copay, for Aetna Part D members whose BMI is >=27 and who also carry heart disease or prediabetes. This one moves. Re-verify against Aetna's primary source each quarter.
Saxenda (liraglutide)The number to notice on Saxenda (liraglutide, for chronic weight management) is 4, not 5. Where Wegovy and Zepbound renew on a >=5% body-weight loss, bulletin 1227-C P08-2024_R (12/19/2024) renews Saxenda at >=4% of baseline, or a maintained 4% loss. Ages 12-17 renew on a different measure again: >=1% reduction in BMI from baseline. Getting in is otherwise familiar. BMI >=30 gets an adult in on its own. At BMI >=27 there has to be a weight-related comorbid condition alongside it, and the bulletin names hypertension, type 2 diabetes mellitus and dyslipidemia. On top of that sits at least 6 months in a comprehensive weight-management program before drug therapy, which Aetna defines as three things run together with continuing follow-up: behavioral modification, increased physical activity, and a reduced-calorie diet. For ages 12-17 the entry threshold is a BMI corresponding to >=30 kg/m^2 in adults by the international Cole Criteria cut-offs, on that same 6-month program. One exclusion to plan around: when the CMS Medicare GLP-1 Bridge takes effect on 07/01/2026, Saxenda is NOT in it. Dispensing caps: 1 package of five 3 mL pens (15 mL) per 25 days, or 3 packages (45 mL) per 75 days.
Copay when it is covered$25-$80 / month

What a GLP-1 costs a Aetna member

At Aetna's typical copay of $25-$80 a month, a covered year of a GLP-1 costs $300 to $960. That is $3,228 to $3,888 less than a year of Wegovy bought for cash from NovoCare ($4,188), and Zepbound's LillyDirect price of $299 to $449 a month is further above it still.

The cheapest compounded option, Collective at $59/mo ($708 a year), lands inside the Aetna range, and 9 sellers charge no more than the $80 top of it, so for a member facing that copay a denial costs less than it sounds.

When Aetna covers the drug, a manufacturer savings card can bring a Wegovy or Zepbound fill down to $25, with each maker paying at most $100 a month.

Employers whose plans run through Aetna

Your employer decides much of this. Among the employers in our coverage checker, 4 use Aetna to run medical or pharmacy benefits: Amazon, JPMorgan Chase, US Postal Service (PSHB) and Brookfield. Amazon's Wegovy position, for example: Covered via 9amHealth weight management program for clinically eligible employees and adult dependents (BMI >=35 with two or more qualifying conditions); copays/cost-shares apply per medical plan.

After a Denial from Aetna

A Aetna denial leaves two routes: an appeal, and paying cash. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[3]. Compounded semaglutide and tirzepatide from licensed 503A pharmacies[4] cost far less than the brand; the cheapest sellers are listed below.

If a large employer self-funds your Aetna plan, ERISA rather than state insurance law applies and the employer decides whether anti-obesity drugs are covered[2]; the Summary Plan Description says which.

Aetna's PA criteria, quoted from the bulletins

Every Aetna GLP-1 bulletin is reproduced word for word in our guide: the CVS Caremark formulary swap of July 2025 that made Wegovy preferred, which drives most 2026 denials; the metformin-first step rule on Mounjaro and Ozempic; the Zepbound 6981-A exception, carried on plan codes ACCF, ACF and ACFC, plus SCCF, SF, SFC, VF and VFC; the Wegovy reauth window of 7 months; the Saxenda continuation threshold set at 4% (NOT 5%); the CMS Medicare GLP-1 Bridge, which starts 07/01/2026; and how Foundayo is handled. Read it in the Aetna GLP-1 Prior Authorization Guide.

Where to go if Aetna says no

Sellers that say they work with Aetna

Sellers that mention Aetna
#SellerCash priceVisit
1EvernowPrice not publishedVisit
2MetoPrice not publishedVisit
3Enara HealthPrice not publishedVisit

The 8 cheapest cash-pay compounded GLP-1s

Cheapest cash-pay compounded GLP-1 sellers
#SellerMonthly priceVisit
1Collective
Compounded semaglutide
$59/moVisit
2Boston Medical Group
Compounded semaglutide
$66/moVisit
3OurView Health
Compounded semaglutide
$75/moVisit
4Ivim Health
Compounded semaglutide
$75/moVisit
5Embody
Compounded semaglutide
$79/moVisit
6Lean Meds
Compounded semaglutide
$79/moVisit
7NextMeds
Compounded semaglutide
$79/moVisit
8NuuVim
Compounded semaglutide
$79/moVisit

Every seller and price, side by side: compare all sellers.

Our picks

#ProviderScore
1Trimi HealthVisit
2EmbodyVisit
3CoreAge RxVisit
4bmiMDVisit
5Live VitalVisit

Frequently Asked Questions

Start with the PBM, because it decides more here than the medical policy does. CVS Caremark - Aetna's PBM, both CVS Health subsidiaries - named Wegovy the PREFERRED commercial GLP-1 in July 2025, so most Aetna commercial books now step members toward it rather than away from it. The policy itself is bulletin 4774-C UDR 08-2023 v2, in force since 05/01/2024 across Non-Medicare commercial plans. An adult has to be >=18 with BMI >=30, or BMI >=27 carrying one weight-related comorbidity, and must already have completed at least 6 months in a comprehensive weight-management program before drug therapy starts. Approval lands at 7 months. Reauthorization then runs 12 months at a time and will not issue unless the chart shows baseline body weight down by 5% or more, or a 5% loss held steady. Ages 12-17 enter at BMI in the 95th percentile or greater, on the same 6-month program requirement. 4774-C carries a second, distinct cardiovascular risk-reduction pathway for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days.
Bulletin 2439-C UDR 05-2024 is the governing document, last reviewed by Aetna on 10/27/2024, and it is a type 2 diabetes policy throughout - Aetna Medicare Part D covers Ozempic on that diagnosis and NOT for off-label weight loss. The initial gate has two halves. The patient must NOT already be on stable GLP-1 maintenance of >=3 months, and must clear at least one of four entry routes: (1) metformin has failed, been contraindicated, or not been tolerated; (2) a need for combination therapy together with A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. That fourth route tracks the label's cardiovascular claim, which the bulletin frames as reducing the risk of 'major adverse cardiovascular events' in adults carrying both type 2 diabetes mellitus and established cardiovascular disease. Continuation inverts the first half: stable maintenance of >=3 months is now required, together with a demonstrated A1C reduction since GLP-1 therapy began. Quantity limits read differently by strength but land in the same place. Per 21 days: 1 pen at 2 mg/1.5 mL, 1 pen at 4 mg/3 mL, 1 pen at 8 mg/3 mL.
Two things decide a Zepbound claim at Aetna, and the bulletin is only one of them. The bulletin is 6947-C P04-2025, effective 07/01/2025 on Non-Medicare commercial plans, superseding the older 6192-C. Adults qualify at BMI >=30, or BMI >=27 alongside a weight-related comorbid condition - hypertension, type 2 diabetes mellitus and dyslipidemia are the examples given - and must have spent at least 6 months in a comprehensive weight-management program before drug therapy. Renewal turns on documented >=5% loss from baseline body weight. A separate route covers moderate-to-severe OSA in adults with obesity at AHI >=15 events/hour. The other thing is the formulary, and it is where members actually get caught. Exception bulletin 6981-A P04-2025 takes over on eight plan-formulary codes - SF, SFC, VF, VFC, ACF, ACFC, ACCF and SCCF - where Wegovy is the preferred step instead. Behind that sits the July 2025 CVS Caremark decision that stripped Zepbound out of MOST commercial formularies, leaving one preferred GLP-1 in its place - which is why a member approved in 2024 can be denied now with nothing in their own file having changed. On the Medicare side, Part D does NOT cover Zepbound for weight loss under the statutory exclusion, though the OSA indication may be payable. From 07/01/2026 the only formulation reaching MA-PD members through the CMS Medicare GLP-1 Bridge is the KwikPen - not vials, not single-dose pens. Quantity limits hold across every strength: 1 package of 4 pens (2 mL) per 21 days, or 3 packages (6 mL) per 63 days.
Bulletin 5468-C UDR 05-2024, which Aetna last reviewed on 10/27/2024. As with Ozempic this is a diabetes policy: Aetna Medicare Part D pays on type 2 diabetes and NOT for off-label weight loss. Aetna writes the initial test as a negative - the patient must NOT already have held 'a stable maintenance dose' for 3 months or more - and then requires one of two routes: metformin inadequacy, intolerance or contraindication, or a need for combination therapy together with A1C >=7.5%. Continuation flips it. Stable maintenance of >=3 months becomes the requirement, paired with a demonstrated A1C reduction, and the approval period is a long one at 36 months. Quantity limits come as two windows, single-dose pens or vials either way: 4 of them (2 mL) across 21 days, or 12 (6 mL) across 63 days.
Foundayo (orforglipron) is the gap in Aetna's published record. We checked aetna.com on 2026-05-09 and found no primary-source PA bulletin for it; FDA approval came 04/01/2026 and the bulletins had not caught up. Until one appears the decision sits with the individual plan or employer, which is a different answer from a denial. Where a plan does pay, the reasonable expectation is that 4774-C, the Wegovy framework, is what gets applied: BMI >=30 on its own or >=27 with a comorbidity, 6 months of comprehensive weight-management program behind the patient, and a 5% continuation test. Medicare is the clearer half. Every Foundayo formulation sits inside the CMS Medicare GLP-1 Bridge from 07/01/2026 through 12/31/2027, at a flat $50/month copay, for Aetna Part D members whose BMI is >=27 and who also carry heart disease or prediabetes. This one moves. Re-verify against Aetna's primary source each quarter.
The number to notice on Saxenda (liraglutide, for chronic weight management) is 4, not 5. Where Wegovy and Zepbound renew on a >=5% body-weight loss, bulletin 1227-C P08-2024_R (12/19/2024) renews Saxenda at >=4% of baseline, or a maintained 4% loss. Ages 12-17 renew on a different measure again: >=1% reduction in BMI from baseline. Getting in is otherwise familiar. BMI >=30 gets an adult in on its own. At BMI >=27 there has to be a weight-related comorbid condition alongside it, and the bulletin names hypertension, type 2 diabetes mellitus and dyslipidemia. On top of that sits at least 6 months in a comprehensive weight-management program before drug therapy, which Aetna defines as three things run together with continuing follow-up: behavioral modification, increased physical activity, and a reduced-calorie diet. For ages 12-17 the entry threshold is a BMI corresponding to >=30 kg/m^2 in adults by the international Cole Criteria cut-offs, on that same 6-month program. One exclusion to plan around: when the CMS Medicare GLP-1 Bridge takes effect on 07/01/2026, Saxenda is NOT in it. Dispensing caps: 1 package of five 3 mL pens (15 mL) per 25 days, or 3 packages (45 mL) per 75 days.
Members who are approved typically pay $25-$80 a month, which is $300 to $960 over a year. A manufacturer savings card can lower that further when the plan covers the drug.
Appeal first: ask Aetna for the written denial and the criteria it applied, and have your prescriber answer them in a letter of medical necessity. If the appeal fails, the cheapest cash route is compounded semaglutide or tirzepatide, from Collective at $59/mo or Boston Medical Group at $66/mo. Sellers that say they work with Aetna include Evernow, Meto and Enara Health. A compounded drug is not FDA-approved as a finished product.

Glossary

The words sellers use, defined. Tap any term.

How coverage looks nationallyWork out the cash-pay difference
Sources & methodology — as of September 2026
  1. 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
  2. 2.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
  3. 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.